Your browser doesn't support javascript.
loading
Prognostic significance of p16 in squamous cell carcinoma of the larynx and hypopharynx.
Meshman, Jessica; Wang, Pin-Chieh; Chin, Robert; John, Maie St; Abemayor, Elliot; Bhuta, Sunita; Chen, Allen M.
Afiliação
  • Meshman J; Departments of Radiation Oncology, University of California, Los Angeles, David Geffen School of Medicine.
  • Wang PC; Departments of Radiation Oncology, University of California, Los Angeles, David Geffen School of Medicine.
  • Chin R; Departments of Radiation Oncology, University of California, Los Angeles, David Geffen School of Medicine.
  • John MS; Otolaryngology- Head and Neck Surgery, University of California, Los Angeles, David Geffen School of Medicine.
  • Abemayor E; Otolaryngology- Head and Neck Surgery, University of California, Los Angeles, David Geffen School of Medicine.
  • Bhuta S; Pathology, University of California, Los Angeles, David Geffen School of Medicine.
  • Chen AM; Departments of Radiation Oncology, University of California, Los Angeles, David Geffen School of Medicine. Electronic address: achen5@kumc.edu.
Am J Otolaryngol ; 38(1): 31-37, 2017.
Article em En | MEDLINE | ID: mdl-27751621
ABSTRACT

PURPOSE:

To evaluate the prognostic significance of p16 expression among patients with squamous cell carcinoma of the larynx (LSCC) and hypopharynx (HSCC).

METHODS:

The medical records of all patients with locally advanced, non-metastatic LSCC/HSCC were reviewed. p16INK4A (p16) protein expression was evaluated on pathological specimens by immunohistochemistry (IHC), and the Kaplan-Meier method was used to estimate overall survival (OS) and locoregional control (LRC). In select cases, p16 expression was correlated to high-risk and low-risk HPV genotypes using in situ hybridization (ISH).

RESULTS:

Thirty-one patients (23 LSCC; 8 HSCC) were identified. Seventeen (54.8%) patients were p16 negative; 14 (45.2%) were p16-positive. The primary treatment modality was radiation therapy for 22 (71.0%) patients and surgery for 9 (29.0%). Nineteen (61.3%) patients were evaluated for high-risk HPV and low-risk HPV genotypes by IHC, of whom 2 (10.5%) patients were positive for high-risk HPV and 1 (5.3%) was positive for low-risk HPV. For high-risk HPV, the positive predictive value (PPV), sensitivity, and specificity of p16 was 20.0%, 100%, and 52.9%. There was no significant difference in the 2-year actuarial rates of OS (91% vs. 64%, p=0.34) or LRC (51% vs. 46%, p=0.69) between the p16-positive and p-16 negative patients.

CONCLUSION:

In this small cohort of 31 LSCC and HSCC patients, p16 was not a significant predictive of either LRC or OS. Furthermore, p16 was poorly correlated with HPV genotyping as identified by ISH.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Papillomaviridae / Carcinoma de Células Escamosas / Regulação Neoplásica da Expressão Gênica / Neoplasias Laríngeas / Infecções por Papillomavirus Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Papillomaviridae / Carcinoma de Células Escamosas / Regulação Neoplásica da Expressão Gênica / Neoplasias Laríngeas / Infecções por Papillomavirus Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article